Online inquiry

IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13376MR)

This product GTTS-WQ13376MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets LRRC15 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001135057.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 131578
UniProt ID Q8TF66
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ13376MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ480MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ631MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ11268MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI4893
GTTS-WQ7705MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GEXMab73
GTTS-WQ9191MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMGN853
GTTS-WQ5835MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ1941MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AGS15C
GTTS-WQ15506MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA UCB-7665
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW